Why would a successful CEO step down at the peak of his career? That’s the question on everyone’s mind as Dr. Kevin Tabb, the long-serving CEO of Beth Israel Lahey Health, announces his departure. But here’s where it gets intriguing: Tabb’s decision comes at a time when the health system is thriving—reporting a $100 million operating gain last year, its first profitable year in four. Employee satisfaction is high, with a majority expressing happiness and willingness to recommend the workplace. Plus, the organization has expanded its primary care team significantly, even attracting talent from rival Mass General Brigham. So, why now?
Tabb himself explains, ‘It’s because things are good. We have momentum, financial stability, and strong partnerships. The work isn’t done, but the foundation is solid. And because we have such a capable team, I feel confident it’s time for the next leader.’ But is it ever truly the ‘perfect time’ to leave a role like this? And this is the part most people miss: stepping down at the peak allows Tabb to leave a legacy of success, but it also raises questions about the challenges his successor will face.
By the time Tabb steps down next year, he will have led the health system for 15 years, making him Massachusetts’ longest-serving hospital network CEO. His next steps remain unclear, though he’s ruled out leading another large-scale organization. ‘I don’t intend to run another hospital or health system,’ he said. ‘If I wanted to, I already lead one I love and believe is the best.’ As for what’s next? ‘I genuinely don’t know.’
Tabb’s journey is nothing short of remarkable. Raised in Berkeley, California, he moved to Israel at 18 to serve in the Israel Defense Forces. After earning his undergraduate and medical degrees from Hebrew University, he completed his residency at Hadassah Hospital in Jerusalem. His career then took him to Stanford Hospital & Clinics before he joined Beth Israel Deaconess Medical Center in 2011.
Ann-Ellen Hornidge, chair of the board of trustees, calls Tabb’s departure a ‘huge loss’ both professionally and personally. ‘It’s a hard job, and the pandemic years were like dog years,’ she said. ‘I understand why he wants to step down.’ The search for his replacement will span eight to 10 months, with both internal and external candidates considered. Hornidge and board vice chair Ron O’Hanley will co-lead the process.
Governor Maura Healey praised Tabb’s leadership, saying, ‘During crises, from the Marathon bombings to the COVID-19 pandemic, Kevin has always stepped up for Massachusetts. His leadership has strengthened healthcare across our state.’
But here’s where it gets controversial: the organization Tabb leaves behind is vastly different from the one he inherited. When he started, Beth Israel Deaconess was a smaller system, comprising only the downtown Boston campus and a community hospital in Needham. Under his leadership, it expanded to include hospitals in Milton and Plymouth, and in 2019, merged with Lahey Health to form Beth Israel Lahey Health—a move that was both ambitious and fraught with challenges.
Merging two organizations is never easy, but the combined entity faced additional hurdles, including a seven-year price cap imposed by the state—a restriction no other health system in the market faced. Then came the pandemic, testing the organization with a surge of critical patients, PPE shortages, and clinician burnout. Tabb’s dedication to his team’s safety and resource acquisition during this time was unwavering, as Hornidge recalled in an email to employees.
Today, Beth Israel Lahey Health serves 1.7 million patients annually, with 64% of care delivered outside its Boston and Burlington hospitals. The system has also invested heavily in primary care, growing its provider base by 30% in the last four years. But challenges remain: Medicaid reimbursement cuts, rising uninsured rates, and escalating costs are just a few issues Tabb’s successor will inherit. ‘It’s the perfect time for someone to come and work on these things for the next 15 years,’ Tabb said.
One of Tabb’s most notable achievements was the partnership with Dana-Farber Cancer Institute, which shocked the medical world in 2023. Dana-Farber will build a new cancer hospital with Beth Israel Deaconess, ending its long-standing relationship with Brigham and Women’s Hospital. While the deal has regulatory approval, the real work is just beginning—construction is expected to complete by 2031, and Beth Israel will need to significantly expand its staff to handle the hospital side of cancer care.
Dr. Benjamin L. Ebert, CEO of Dana-Farber, credited Tabb’s leadership, saying, ‘This collaboration would not have been possible without Kevin’s integrity and commitment to patients.’
But here’s the question we leave you with: As Tabb steps down, is the healthcare system he leaves behind truly prepared for the challenges ahead? And what does his departure say about the future of leadership in an industry facing unprecedented pressures? Let us know your thoughts in the comments—we’d love to hear your take on this pivotal moment in healthcare leadership.
